Q-omics provides the consensus-scored CHORDC1P4 profile across patient tissues and cancer cell-line models. CHORDC1P4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CHORDC1P4 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, CHORDC1P4 RNA expression shows 16,886 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight UCEC, STAD, and DLBC as cancer lineages where CHORDC1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHORDC1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHORDC1P4 survival associations across molecular data types. CHORDC1P4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHORDC1P4 RNA expression–survival associations across cancer types. High CHORDC1P4 expression shows unfavorable associations in UCEC, KIRC, LGG, MESO and ACC, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UCEC as the clearest survival context for CHORDC1P4 RNA expression.
This table summarizes CHORDC1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CHORDC1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHORDC1P4 shows lower tumor expression in KIRP and KIRC and higher tumor expression in STAD, HNSC, BRCA and ESCA. The STAD box plot shows higher CHORDC1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.395, t-test p < 0.001).
This table shows molecular features associated with CHORDC1P4 in patient tissues and cancer cell lines. In patient samples, CHORDC1P4 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHORDC1P4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
